Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 67

Sort by

Sort Order Select

Journal Articles

The Combination of the BCL-2 Antagonist Venetoclax with the CD70-Targeting Antibody Cusatuzumab Synergistically Eliminates Primary Human Leukemia Stem Cells

Carsten Riether, PhD, Tanja Chiorazzo, PhD, Amy J. Johnson, PhD, Christina Diane Drenberg, PhD, Khaja Waheeduddin Syed, BPharm, MS, Mahan Moshir, MSc, Anna Hultberg, PhD, Nicolas Leupin, Hans De Haard, Adrian F Ochsenbein, MD

Blood (2019) 134 (Supplement_1): 3918.

https://doi.org/10.1182/blood-2019-127464

Published: 2019

Journal Articles

Activating MAPK Pathway Mutations Mediate Primary Resistance to PI3K Inhibitors in Chronic Lymphocytic Leukemia (CLL)

Ishwarya Murali, PhD BS, Siddha Kasar, PhD, Emily M. McWilliams, PhD, Gilad Itchaki, Svitlana Tyekucheva, PhD, Dimitri Livitz, BS, Ignaty Leshchiner, PhD, Shuai Dong, PhD, Stacey M. Fernandes, BS, Gad Getz, PhD, Amy J. Johnson, PhD, Jennifer R. Brown, MD PhD

Blood (2018) 132 (Supplement 1): 587.

https://doi.org/10.1182/blood-2018-99-115304

Published: 2018

Journal Articles

JNJ-64457107, a CD40 Agonist, Induces Cell Death in BCL6 hi IRF4 neg GCB Subtype of DLBCL

Joshua J. Rusbuldt, MA, Andressa A. Smith, PhD, Sriram Balasubramanian, Gary Borzillo, PhD, Amy J. Johnson, PhD, Diana Alvarez Arias, PhD

Blood (2018) 132 (Supplement 1): 1674.

https://doi.org/10.1182/blood-2018-99-114622

Published: 2018

Journal Articles

Inhibitors of Bruton's Tyrosine Kinase Reduce Anti-Red Blood Cell Response in a Murine Model of Autoimmune Hemolytic Anemia

Kerry A. Rogers, MD, Amy M. Lehman, MAS, Carolyn Cheney, BS, Virginia M. Goettl, DVM , PhD, Rose Mantel, Lisa L. Smith, MS, Minh Tran, Amy J. Johnson, PhD, John C. Byrd, MD, Jennifer A. Woyach, MD

Blood (2016) 128 (22): 1259.

https://doi.org/10.1182/blood.V128.22.1259.1259

Published: 2016

Journal Articles

Exploring the Functional Relevance of BTK Beyond Chronic Lymphocytic Leukemia (CLL) Cells: BTK Expression in Non-Malignant Immune Cells of the Microenvironment Mediates CLL Development and Progression In Vivo

Fabienne McClanahan, MD PhD, Sean D. Reiff, Daphne Guinn, PhD, Minh Tran, Larry Beaver, Samantha McWorther, Rose Mantel, Lisa L. Smith, MS, Amy J. Johnson, PhD, John C. Byrd, MD, Jennifer A. Woyach, MD

Blood (2016) 128 (22): 352.

https://doi.org/10.1182/blood.V128.22.352.352

Published: 2016

Journal Articles

The Bruton's Tyrosine Kinase (BTK) Inhibitor ARQ 531 Effectively Inhibits Wild Type and C481S Mutant BTK and Is Superior to Ibrutinib in a Mouse Model of Chronic Lymphocytic Leukemia

Sean D. Reiff, Rose Mantel, Lisa L. Smith, MS, Samantha McWhorter, Virginia M. Goettl, DVM , PhD, Amy J. Johnson, PhD, Sudharsan Eathiraj, Giovanni Abbadessa, MD, Brian Schwartz, MD, John C. Byrd, MD, Jennifer A. Woyach, MD

Blood (2016) 128 (22): 3232.

https://doi.org/10.1182/blood.V128.22.3232.3232

Published: 2016

Journal Articles

Ibrutinib Represents a Novel Class of Immune Modulating Therapeutics That Enhances the Survival of Activated T Cells in Vitro and In Vivo through a Non-BTK Mediated Mechanism

Meixiao Long, MD PhD, Kyle A. Beckwith, PhD, Priscilla Do, BS, Mundy L Bethany, PhD, Gordon Gordon, Amy M. Lehman, MAS, Kami J. Maddocks, MD, Carolyn Cheney, BS, Jeffrey Jones, MD MPH, Leslie A. Andritsos, MD, Farrukh T. Awan, Joseph A. Fraietta, PhD, Carl H June, MD, Marcela V. Maus, MDPhD, Jennifer A. Woyach, MD, Michael A. Caligiuri, MD, Amy J. Johnson, PhD, Natarajan Muthusamy, DVM, PhD, John C. Byrd, MD

Blood (2016) 128 (22): 3238.

https://doi.org/10.1182/blood.V128.22.3238.3238

Published: 2016

Journal Articles

Near-Tetraploidy Is Strongly Associated with Development of Richter's Transformation in Chronic Lymphocytic Leukemia Patients Receiving Ibrutinib

Blood (2016) 128 (22): 3198.

https://doi.org/10.1182/blood.V128.22.3198.3198

Published: 2016

Journal Articles

the Development and Expansion of Resistant Subclones Precedes Relapse during Ibrutinib Therapy in Patients with CLL

Blood (2016) 128 (22): 55.

https://doi.org/10.1182/blood.V128.22.55.55

Published: 2016

Journal Articles

Five-Year Experience with Single-Agent Ibrutinib in Patients with Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia

Susan M. O'Brien, MD, Richard R. Furman, MD, Steven E. Coutre, MD, Ian W. Flinn, MD PhD, Jan Burger, MD PhD, Kristie Blum, MD, Jeff Sharman, MD, William G. Wierda, MD PhD, Jeffrey Jones, MD MPH, Weiqiang Zhao, MD PhD, Nyla A. Heerema, PhD, Amy J. Johnson, PhD, Ying Luan, PhD, Danelle F. James, MD MAS, Alvina D. Chu, MD, John C. Byrd, MD

Blood (2016) 128 (22): 233.

https://doi.org/10.1182/blood.V128.22.233.233

Published: 2016

Journal Articles

Interim Results of a Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination with Chemotherapy in Patients with Acute Myeloid Leukemia

Alison R. Walker, MD MPH, Bhavana Bhatnagar, DO, A. Mario Q. Marcondes, MD, Julie DiPaolo, PhD, Sumithra Vasu, MBBS, Alice S. Mims, MD MSCR, Rebecca B. Klisovic, MD, Katherine J. Walsh, MD, Renee Canning, RN, Gregory K. Behbehani, MD PhD, Ramiro Garzon, MD, James S. Blachly, MD, Amy J. Johnson, PhD, Esteban Abella-Dominicis, John C. Byrd, MD, William Blum, MD

Blood (2016) 128 (22): 2831.

https://doi.org/10.1182/blood.V128.22.2831.2831

Published: 2016

Journal Articles

A Phase 2 Study of Lenalidomide to Repair Immune Synapse Response and Humoral Immunity in Early-Stage, Asymptomatic Chronic Llmphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) with High-Risk Genomic Features

Jeffrey A. Jones, MD MPH, Amy J. Johnson, PhD, Farrukh T. Awan, Quihong Zhao, MAS, Natarajan Muthusamy, DVM, PhD, Kami J. Maddocks, MD, Leslie A. Andritsos, MD, Kerry A. Rogers, MD, Jennifer A. Woyach, MD, Gerard Lozanski, MD, Nyla A. Heerema, PhD, Cathy Brookfield, BSN, Amy S Ruppert, MAS, John C. Byrd, MD

Blood (2016) 128 (22): 4388.

https://doi.org/10.1182/blood.V128.22.4388.4388

Published: 2016

Journal Articles

Ibrutinib Treatment Reduces Both T-Regulatory Cells and B-Regulatory Cell Phenotype in Malignant B Cells in Chronic Lymphocytic Leukemia Patients

Meixiao Long, MD PhD, Kyle A. Beckwith, BS, Kami J. Maddocks, MD, Carolyn Cheney, BS, Jennifer A. Woyach, MD, Amy J. Johnson, PhD, Natarajan Muthusamy, DVM, PhD, John C. Byrd, MD

Blood (2015) 126 (23): 2940.

https://doi.org/10.1182/blood.V126.23.2940.2940

Published: 2015

Journal Articles

ACP-196 Is a Second Generation Inhibitor of Bruton Tyrosine Kinase (BTK) with Enhanced Target Specificity

Bonnie K. Harrington, DVM, Michael Gulrajani, BS, Todd Covey, Allard Kaptein, PhD, Bart Van Lith, Raquel Izumi, PhD, Ahmed Hamdy, MBBCh, Roger Glenn Ulrich, PhD, John C Byrd, MD, Brian J Lannutti, PhD, Amy J. Johnson, PhD

Blood (2015) 126 (23): 2908.

https://doi.org/10.1182/blood.V126.23.2908.2908

Published: 2015

Journal Articles

The Bruton Tyrosine Kinase (BTK) Inhibitor ACP-196 Demonstrates Clinical Activity in Two Mouse Models of Chronic Lymphocytic Leukemia

Sarah E. M. Herman, PhD, Arnau Montraveta, BS, Carsten U Niemann, MD PhD, Helena Mora-Jensen, PhD, Michael Gulrajani, BS, Fanny Krantz, Bonnie K. Harrington, DVM, Todd Covey, Brian J Lannutti, PhD, Raquel Izumi, PhD, Roger G Ulrich, PhD, John C. Byrd, MD, Adrian Wiestner, MD PhD, Amy J. Johnson, PhD, Jennifer A. Woyach, MD

Blood (2015) 126 (23): 2920.

https://doi.org/10.1182/blood.V126.23.2920.2920

Published: 2015

Journal Articles

The Eµ-Myc/TCL1 Transgenic Mouse As a New Aggressive B-Cell Malignancy Model Suitable for Preclinical Therapeutics Testing

Kerry A. Rogers, MD, Dalia El-Gamal, PhD, Harrington K. Bonnie, DVM, Hing A. Zachary, BS, Goettl M. Virginia, DVM, PhD, Mantel Rose, Lisa L. Smith, MS, Lianbo Yu, PhD, Amy J. Johnson, PhD, John C. Byrd, MD, Rosa Lapalombella, PhD, Jennifer A. Woyach, MD

Blood (2015) 126 (23): 2752.

https://doi.org/10.1182/blood.V126.23.2752.2752

Published: 2015

Journal Articles

Genetic Inhibition of PI3K p110delta Antagonizes Survival Signals and Induces Immune Activation in Chronic Lymphocytic Leukemia (CLL)

Shuai Dong, MS, John C. Byrd, MD, Amy J. Johnson, PhD

Blood (2015) 126 (23): 1711.

https://doi.org/10.1182/blood.V126.23.1711.1711

Published: 2015

Journal Articles

NFkB p50 ( Nfkb1 ) Contributes to Disease in the Eu-TCL1 Mouse Model of Chronic Lymphocytic Leukemia

Erin K Hertlein, PhD, Timothy L Chen, David M Lucas, PhD, Nikhil Gupta, Jessica MacMurray, Virginia M. Goettl, DVM , PhD, Amy M. Lehman, MAS, Amy J. Johnson, PhD, John C Byrd, MD

Blood (2015) 126 (23): 1248.

https://doi.org/10.1182/blood.V126.23.1248.1248

Published: 2015

Journal Articles

Targeting BTK By a microRNA Mechanism in Chronic Lymphocytic Leukemia

Arianna Bottoni, Rizzotto Lara, PhD, Lai Tzung-Huei, PhD, Rose Mantel, Lisa Simith, Dalia El-Gamal, PhD, Amy J. Johnson, PhD, Rosa Lapalombella, PhD, James S. Blachly, MD, John C. Byrd, MD, Jennifer A. Woyach, MD, Deepa Sampath, PhD

Blood (2015) 126 (23): 1232.

https://doi.org/10.1182/blood.V126.23.1232.1232

Published: 2015

Journal Articles

Pharmacologic Inhibition with Duvelisib (IPI-145) and Genetic Inhibition of PI3K p110δ Antagonizes Intrinsic and Extrinsic Survival Signals in Chronic Lymphocytic Leukemia (CLL)

Shuai Dong, MS, Daphne Guinn, Jason A Dubovsky, PhD, Yiming Zhong, PhD, Amy Lehman, Jeff Kutok, MD, PhD, Jennifer A. Woyach, MD, John C. Byrd, MD, Amy J. Johnson, PhD

Blood (2014) 124 (21): 3324.

https://doi.org/10.1182/blood.V124.21.3324.3324

Published: 2014

NARROW

The Combination of the BCL-2 Antagonist Venetoclax with the CD70-Targeting Antibody Cusatuzumab Synergistically Eliminates Primary Human Leukemia Stem Cells

Activating MAPK Pathway Mutations Mediate Primary Resistance to PI3K Inhibitors in Chronic Lymphocytic Leukemia (CLL)

JNJ-64457107, a CD40 Agonist, Induces Cell Death in BCL6 hi IRF4 neg GCB Subtype of DLBCL

Inhibitors of Bruton's Tyrosine Kinase Reduce Anti-Red Blood Cell Response in a Murine Model of Autoimmune Hemolytic Anemia

Exploring the Functional Relevance of BTK Beyond Chronic Lymphocytic Leukemia (CLL) Cells: BTK Expression in Non-Malignant Immune Cells of the Microenvironment Mediates CLL Development and Progression In Vivo

The Bruton's Tyrosine Kinase (BTK) Inhibitor ARQ 531 Effectively Inhibits Wild Type and C481S Mutant BTK and Is Superior to Ibrutinib in a Mouse Model of Chronic Lymphocytic Leukemia

Ibrutinib Represents a Novel Class of Immune Modulating Therapeutics That Enhances the Survival of Activated T Cells in Vitro and In Vivo through a Non-BTK Mediated Mechanism

Near-Tetraploidy Is Strongly Associated with Development of Richter's Transformation in Chronic Lymphocytic Leukemia Patients Receiving Ibrutinib

the Development and Expansion of Resistant Subclones Precedes Relapse during Ibrutinib Therapy in Patients with CLL

Five-Year Experience with Single-Agent Ibrutinib in Patients with Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia

Interim Results of a Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination with Chemotherapy in Patients with Acute Myeloid Leukemia

A Phase 2 Study of Lenalidomide to Repair Immune Synapse Response and Humoral Immunity in Early-Stage, Asymptomatic Chronic Llmphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) with High-Risk Genomic Features

Ibrutinib Treatment Reduces Both T-Regulatory Cells and B-Regulatory Cell Phenotype in Malignant B Cells in Chronic Lymphocytic Leukemia Patients

ACP-196 Is a Second Generation Inhibitor of Bruton Tyrosine Kinase (BTK) with Enhanced Target Specificity

The Bruton Tyrosine Kinase (BTK) Inhibitor ACP-196 Demonstrates Clinical Activity in Two Mouse Models of Chronic Lymphocytic Leukemia

The Eµ-Myc/TCL1 Transgenic Mouse As a New Aggressive B-Cell Malignancy Model Suitable for Preclinical Therapeutics Testing

Genetic Inhibition of PI3K p110delta Antagonizes Survival Signals and Induces Immune Activation in Chronic Lymphocytic Leukemia (CLL)

NFkB p50 ( Nfkb1 ) Contributes to Disease in the Eu-TCL1 Mouse Model of Chronic Lymphocytic Leukemia

Targeting BTK By a microRNA Mechanism in Chronic Lymphocytic Leukemia

Pharmacologic Inhibition with Duvelisib (IPI-145) and Genetic Inhibition of PI3K p110δ Antagonizes Intrinsic and Extrinsic Survival Signals in Chronic Lymphocytic Leukemia (CLL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only